Clinical trial · no report yet · Phase 2
SU2C-SARC032
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
- NCT03092323 ↗
- Active, not recruiting
- Sarcoma Alliance for Research through Collaboration
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 10 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Soft Tissue Sarcoma of the Extremity
- Interventions
- Pembrolizumab
- Arms
- Treatment · Experimental
- Standard of Care · No intervention
- Enrollment
- 126 (estimated)
- Primary outcomes
- Disease free survival
- Sponsor
- Sarcoma Alliance for Research through Collaboration with Stand Up To Cancer, Merck Sharp & Dohme LLC
- Start
- Jul 19, 2017
- Primary completion
- Sep 1, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT03092323 · updated Nov 18, 2023
Publications
linked from the registry- Mowery YM, Ballman KV, Hong AM, Schuetze SM, Wagner AJ, Monga V, Heise RS, Attia S, Choy E, Burgess MA, Bae S, Pryor DI, Van Tine BA, Tinoco G, Chmielowski B, Freeman C, Gronchi A, Meyer CF, Dickson MA, Hartner L, Davis LE, Powers BC, Moding EJ, Weinhold KJ, van de Rijn M, Brigman BE, Riedel RF, Kirsch DG. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. Lancet. 2024 Nov 23;404(10467):2053-2064. doi: 10.1016/S0140-6736(24)01812-9. Epub 2024 Nov 12. PubMed 39547252